Ac-Phe-Orn(1)-Pro-D-Cha-2Nal-Arg-(1)

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ac-Phe-Orn(1)-Pro-D-Cha-2Nal-Arg-(1)
• 英文别名: (2S)-2-acetamido-N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(naphthalen-2-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide
• 化学式: C₄₉H₆₆N₁₀O₇
• 分子量: 907.1
• InChiKey: LAVIOWMEHKGOMF-PHHHQBPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  66
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  259
• 氢给体数：
  8
• 氢受体数：
  8

文献信息

• Use of C5A receptor antagonist in the treatment of fibrosis
  申请人：Taylor Maxwell Stephen

  公开号：US20080058252A1

  公开（公告）日：2008-03-06

  This invention relates to the use of an antagonist of a G protein-coupled receptor in the prevention and/or treatment of fibrosis, such as the treatment of fibrosis associated with myocardial infarction or diabetes or certain pulmonary conditions. In a preferred embodiment, the antagonist is a C5a receptor antagonist, more preferably a cyclic peptide antagonist of the C5a receptor. In particular, the invention provides a method of prevention, treatment or alleviation of a fibrotic condition, comprising the step of administering an effective amount of an antagonist of a G protein-coupled receptor to a subject in need of such treatment.